top of page

Changing the Conversation


Autoimmune Disease Treatment

The Problem

Patients who suffer from autoimmune disease accept chronic management of symptoms through nonspecific immunosuppressant as the standard of treatment. These treatments along with medications ranging from cyclophosphamide to biologic therapies are associated with an increased risk for infections as well as significant adverse effects including hepatotoxicity, gastrointestinal perforation, and fatigue.


An optimal treatment strategy for autoimmune disease would specifically target disease associated antigens and limit systemic side effects. Many recent approaches have focused on the development of curative, antigen specific immunotherapies (ASI); however, the market has seen little clinical success. Promising animal studies of ASI have not yet been translated into clinical efficacy.


As such, world-leading immunologists have voiced that a new delivery mechanism that maximizes efficacy is necessary to push the first antigen-specific therapy through FDA approval.

The Problem

Our Solution

An engineered nanoparticle that delivers dual therapeutic agents to the right place at the right time.


Because of the spatial and temporal control, we achieve better results in addition to lowering concentration, frequency, and side effects.

Spatiotemporally Tuned Particles


Our Solution

Statera’s patented technology, Spatiotemporally Tuned Particles (STP), adds targeting and temporal control to the otherwise free floating drug agents. In encapsulating drug agents in STP, we can achieve optimized, sequential delivery to specific cell targets. STP has been shown to supersede the efficacy of the current standard of combinatorial drug delivery.

Meet Our Team

Meet Our Team

Philip Kong, PhD

  • Grey LinkedIn Icon

A PhD in Immunology from Yale, and a Fulbright Scholar from Cal Tech. Philip has published scientific papers in top-tier journals, such as Cell Host and Microbe.

Colin Picture.jpg

Colin Foster, MBA

  • Grey LinkedIn Icon

Former CEO of Bayer Pharmaceuticals North America.  Over 30 yrs experience as Chairman, CEO, and entrepreneur with leadership experience across the R&D-commercial continuum in therapeutics, diagnostics, and medical devices. Led several biotech companies.


Sean Bickerton, MD/PhD

  • Grey LinkedIn Icon

A MD/PhD candidate at Yale with background in chemistry, drug delivery, and immunotherapy. Sean has published in Journal of the American Chemical Society and Journal of Clinical Investigation.


Owen Yang, MBA

  • Grey LinkedIn Icon

Passionate Healthcare Entrepreneur. MBA graduate from Yale University; 5+ years experience in healthcare technology, overseeing business strategy and implementation, and experience in private equity, investments ranging from $10M to $25M. Recipient of the Yale Marshall and Jay S. Yadav, M.D. Entrepreneurial Fellowship Award.


Have a question about our technology? Interested in a possible partnership? Want to join our team?

Reach out below.

Thank you for reaching out. We will be in touch soon.

Contact Us
bottom of page